Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With Immunoglobulin A Nephropathy on Stable RAAS Blockade

NCT02384317 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02384317
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02384317 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With Immunoglobulin A Nephropathy on Stable RAAS Blockade
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
March 27, 2015
Completion date
June 1, 2018
Enrollment
7 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

immunoglobulin a nephropathy